计算溶液所需的质量、体积或浓度。
提供 ≥98% 纯度,适用于对基线干扰要求严格的色谱和分析工作流程。
-20°C储存。超低温运输 。请查阅批次 COA 获取详细规格。
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
在色谱分析、有机合成和交叉偶联反应领域已被 0 篇同行评审文献引用。
KIF18A-IN-6 (Compound 134) is an orally active KIF18A inhibitor with an IC 50 of 0.016 μM against KIF18A microtubule-dependent ATPase activity
In Vitro
KIF18A-IN-6 (Compound 134; 7 days) inhibits JIMT-1, HCC-15 and NIH-OVCAR3 cells viability with IC 50 s of 0.0040, 0.0051 and 0.0051 μM, respectively. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: HCC-15, JIMT-1 and NIH-OVCAR3 Concentration: Incubation Time: 7 days Result: Inhibited cell viability with IC 50 s of 0.0040, 0.0051 and 0.0051 μM against JIMT-1, HCC-15 and NIH-OVCAR3 cells, respectively.
In Vivo
KIF18A-IN-6 (Compound 134; 10-60 mg/kg; p.o.; twice or once a day for 1 month) inhibits HCC15 and OVCAR3 tumor growth in mice . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: SCID Beige mice, HCC15 tumor model Dosage: 10, 30 and 60 mg/kg Administration: PO, twice a day for 1 month Result: Inhibited tumor growth by 61±10%, 89±7% and 94±5% at 10, 30 and 60 mg/kg, respectively. Animal Model: Balb/C nude mice, OVCAR3 tumor model Dosage: 10, 30 and 60 mg/kg Administration: PO, twice or once a day for 1 month Result: Completely inhibited tumor growth (over 100%) over 30 mg/kg.
Form:Solid
IC50& Target:IC50: 0.016 μM (KIF18A microtubule-dependent ATPase activity)